医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

KYOCERA to Purchase Major Assets of U.S.-based Renovis Surgical Technologies, Inc.

2019年01月16日 PM03:00
このエントリーをはてなブックマークに追加


 

KYOTO, Japan

Kyocera Corporation (TOKYO:6971) today announced that its U.S. headquarters, Kyocera International, Inc., has finalized an agreement with Renovis Surgical Technologies, Inc. (herein “Renovis”), a U.S.-based orthopedic and spinal medical device manufacturer and developer, to purchase the major assets of Renovis’ business operations relating to artificial joint and spinal products.

The assets will be transferred into a new California-based company wholly owned by Kyocera International, Inc., to be named Kyocera Medical Technologies, Inc., in March 2019.

Background and Overview
Kyocera currently manufactures medical products, including artificial joints and dental implants, primarily for the Japanese market. The U.S. orthopedic implant market totals approximately US$20 billion, representing about 60% of the global market, with continued growth expected.* To grow internationally, Kyocera obtained U.S. FDA 510(k) clearance for its artificial hip joints and began selling them in the U.S. in 2017.

Renovis, founded in 2009, is a market leader in 3D-printed implants, and has developed a broad portfolio of innovative products for the U.S. market, serving the needs of orthopedic, neurological, and trauma surgeons. Renovis has experienced steady growth since its inception and has continued to develop and commercialize a wide range of products manufactured using its Tesera Trabecular Technology, a proprietary implant surface structure made using additive manufacturing. In addition, Renovis has developed an advanced bearing surface technology for joint replacement products. Kyocera’s global strength and expansive research and development capabilities will accelerate the growth of these valuable technologies.

Kyocera plans to expand its U.S. medical equipment business through this asset purchase. The newly established company will develop high value-added products that improve patient health and quality of life through synergies between Kyocera’s proprietary technologies and those purchased from Renovis.

* Based on third-party research as of December 2018

 

Overview of Renovis

Company name   Renovis Surgical Technologies, Inc.
Location

Headquarters: Redlands, California, U.S.A.
Development center: Austin, Texas, U.S.A.

President and CEO John C. Steinmann
Employees   44 (as of December 31, 2018)
 

For more information about Renovis: http://www.renovis-surgical.com/

About KYOCERA

Kyocera Corporation (TOKYO:6971) (https://global.kyocera.com/), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of semiconductor packages, industrial and automotive components, electronic devices, solar power generating systems, printers, copiers and mobile phones. During the year ended March 31, 2018, the company’s consolidated net sales totaled 1.58 trillion yen (approx. US$14.9 billion). Kyocera appears on the “Top 100 Global Innovators” list by Clarivate Analytics and is ranked #612 on Forbes magazine’s 2018 “Global 2000” list of the world’s largest publicly traded companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190115006018/en/

CONTACT

KYOCERA Corporation (Japan)
Corporate Communications
Natsuki
Doi, +81-(0)75-604-3416
webmaster.pressgl@kyocera.jp
Fax:
+81-(0)75-604-3516

同じカテゴリーの記事 

  • アクティビストキャンペーンサイトStrengthen Wakamoto(TOKYO:4512)の公開:株式会社ナナホシマネジメント
  • Nanahoshi Management Ltd.: Strengthen Wakamoto Activist Campaign (TOKYO:4512) Is Released
  • 冠科生物连续三年荣膺T+ Employer® 卓越雇主
  • Crown Bioscienceが3年連続でT+ Employer®に認定される
  • Better Foods of Shinsegae Food Participates in NPEW to Accelerate Entry to U.S. Plant-based Food Market